Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myocarditis I: Introduction01:21

Myocarditis I: Introduction

328
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
328
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

229
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
229
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

1.6K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.6K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

1.8K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.8K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.7K
Intralumenal Vesicles and Multivesicular Bodies01:38

Intralumenal Vesicles and Multivesicular Bodies

4.6K
Intraluminal vesicles (ILVs) are small vesicles 50-80 nm in diameter formed during the maturation of early endosomes. A specialized endosome containing numerous ILVs is called a multivesicular body (MVB). ILVs contain internalized molecules such as antigens, nucleic acids, proteins, and metabolites. Some of these molecules are released from the MVBs inside exosomes and are transported to other cells. Other MVBs contain molecules that are retained in the ILVs and are later degraded within the...
4.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unmasking Compound Heterozygosity in GYG1 Myopathy: Diagnostic Insights From RNA-Seq and Long-Read Genomics.

Clinical genetics·2026
Same author

Multilevel impairment of mitochondrial respiration with sex-specific signatures in inclusion body myositis.

bioRxiv : the preprint server for biology·2026
Same author

Spatial transcriptomics reveals mechanism of autoimmunity driven by internalized autoantibodies.

medRxiv : the preprint server for health sciences·2026
Same author

A randomized, double-blind, placebo-controlled study of losmapimod in patients with facioscapulohumeral muscular dystrophy: Results of the REACH study.

Journal of neuromuscular diseases·2026
Same author

Updates on Diagnostic Criteria of Inclusion Body Myositis.

Rheumatic diseases clinics of North America·2025
Same author

Immunoglobulin for myasthenia gravis.

The Cochrane database of systematic reviews·2025

Related Experiment Video

Updated: Jan 6, 2026

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach
09:01

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach

Published on: June 5, 2010

14.6K

Inclusion Body Myositis.

Elie Naddaf

    Continuum (Minneapolis, Minn.)
    |October 2, 2025
    PubMed
    Summary
    This summary is machine-generated.

    Inclusion body myositis (IBM) is a progressive aging-related muscle disease primarily affecting males. Diagnosis integrates clinical data, muscle biopsy, and new criteria, while treatment requires a multidisciplinary approach.

    More Related Videos

    Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
    10:55

    Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

    Published on: October 31, 2025

    636
    Minimally Invasive Muscle Embedding MIME - A Novel Experimental Technique to Facilitate Donor-Cell-Mediated Myogenesis
    09:17

    Minimally Invasive Muscle Embedding MIME - A Novel Experimental Technique to Facilitate Donor-Cell-Mediated Myogenesis

    Published on: August 24, 2017

    8.1K

    Related Experiment Videos

    Last Updated: Jan 6, 2026

    Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach
    09:01

    Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach

    Published on: June 5, 2010

    14.6K
    Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
    10:55

    Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

    Published on: October 31, 2025

    636
    Minimally Invasive Muscle Embedding MIME - A Novel Experimental Technique to Facilitate Donor-Cell-Mediated Myogenesis
    09:17

    Minimally Invasive Muscle Embedding MIME - A Novel Experimental Technique to Facilitate Donor-Cell-Mediated Myogenesis

    Published on: August 24, 2017

    8.1K

    Area of Science:

    • Neurology
    • Rheumatology
    • Genetics

    Background:

    • Inclusion body myositis (IBM) is an aging-related inflammatory myopathy predominantly affecting males.
    • Characterized by slowly progressive muscle weakness, particularly in finger flexors and quadriceps, with potential swallowing and respiratory muscle involvement.
    • Clinical presentation can overlap with other myopathies, and atypical IBM presentations, including isolated dysphagia, are common.

    Purpose of the Study:

    • To outline the clinical presentation, diagnostic workup, and management strategies for IBM.
    • To review the current landscape of clinical trials for IBM.
    • To explore future research directions for effective IBM treatments.

    Main Methods:

    • Diagnosis relies on integrating historical, clinical, and laboratory data.
    • Muscle biopsy remains crucial; cytosolic nucleotidase 1A antibodies and muscle imaging increasingly support diagnosis.
    • The 2024 European Neuromuscular Centre criteria provide a new diagnostic framework.

    Main Results:

    • IBM diagnosis requires a comprehensive approach due to overlapping phenotypes and atypical presentations.
    • Management focuses on a multidisciplinary strategy to handle comorbidities and complications.
    • The development of effective treatments is challenged by IBM's complex pathophysiology and its relation to aging.

    Conclusions:

    • Accurate diagnosis of IBM necessitates careful integration of diverse clinical and diagnostic findings.
    • Effective management of IBM involves addressing associated health issues and complications.
    • Advancing IBM treatment requires unraveling the complexities of aging-related disorders.